The CDC also recommended that people who received the primary vaccine and booster from Johnson & Johnson receive the mRNA booster at least four months after receiving the second dose.
Also today, the Food and Drug Administration released a second booster from Pfizer-BioNTech and Moderna for adults over 50 and announced that a fourth injection would improve protection against severe Covid-19. He also approved a second Pfizer-BioNTech booster for children over 12 years of age with impaired immunity and a second Moderna booster for adults with immunodeficiency over the age of 18 years. Moderna is only valid for adults over 18 years of age.
“Current evidence points to some reduction in protection against the serious effects of Covid-19 in the elderly and immunocompromised individuals,” said Peter Marks, director of the FDA’s Center for Biological Assessment and Research. In the statement. “Based on the analysis of the developed data, a second boost dose of Pfizer-BioNTech or Moderna Covid-19 vaccine may help to increase the level of protection of these high-risk individuals.
Wallpaper: The move comes as the Biden administration and public health experts worry about a potential new increase in cases. Across Europe, the highly infectious BA.2 variant is spreading rapidly, and many fear it will soon lead to a live rise in patients in the US of BA.2, a sub-variant of Omicron, which accounts for more than 54 percent of cases nationwide, accounting for 39 percent. Last week, the Centers for Disease Control and Prevention announced Tuesday.
The decision to permit these boosters is based on data from Israel, where approximately 700,000 adults received the second Pfizer-BioNTech booster. A smaller study was conducted on 120 American adults who received the additional Moderna booster vaccine after receiving the primary Pfizer-BioNTech vaccine. Amplifier. The FDA also examined data on immune responses from individuals who received boosters in Israel as part of an ongoing study, and no side effects were detected in these studies.
Moderna originally asked the FDA to allow a second booster for all adults. Still, the FDA chose to enable it instead only for those with a high risk of developing severe Covid.
“By choosing to be over 50, which we often use for other respiratory viruses, such as the flu, to target people at higher risk, we thought we would restrain the population that would benefit most from this fourth booster dose,” Marx said. Press service with journalists.
The United States has enough booster doses for these populations, said Don O’Connell, secretary of the Department of Health and Human Services for Preparedness and Response, at a news conference Monday. “What worries us is … if another option comes out and we need to strengthen a specific option in a few months. “It will be quite expensive, and we do not have these doses on hand, and we do not currently have the funding to cover these doses,” he added.
Რa is the following: Marx suggested during the call that the agency be prepared to allow even more shots if science shows they provide additional protection.
“People may need to get extra boosters in the fall with a more general boost campaign,” he said.
He said the strategy would be discussed at the Vaccine Advisory Committee’s next meeting, which is scheduled for April 6. In addition to reviewing Covid-19 amplifiers, the committee reviews best practices for companies seeking to design strikes against future virus strains.
Sarah Overmohle contributed to this report.
CDC recommends Pfizer-BioNTech, Moderna Covid-19 vaccine supplement enhancer for adults over 50 years of age
